MedTrace Logo

Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

NCT04646928 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 245

Last updated 2020-11-30

No results posted yet for this study

Summary

To analyze the incidence of liver cancer after entecavir administration among patients with low viral load and cirrhosis due to chronic hepatitis B infection.

Conditions

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    collaborator INDUSTRY

  • CHA University

    lead OTHER

Principal Investigators

  • SungKyu Hwang, MD · Principal Investigator

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-17
Primary Completion
2022-05-28
Completion
2022-08-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04646928 on ClinicalTrials.gov